Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Transplanted beta cells avoid immune attack in mice with type 1 diabetes
A photo through a microscope of the non-engineered (left) and engineered (right) human islets, which contain different hormone producing cells including beta cells. Different hormones are labelled in different colours: green is insulin, red is glucagon and blue is somatostatin.
Genetically engineered beta cells transplanted into mice with type 1 diabetes avoid immune system attack and stabilise blood glucose levels without immunosuppressants.
Researchers from Sana Biotechnology in California took pancreatic islets (clusters of cells in the pancreas) from human donors and took out the insulin-producing beta cells inside them. Next, they genetically engineered these beta cells so the immune system can’t find them. They did this by removing the markers on the surface of the cells that immune cells can detect. Then the researchers let the genetically modified beta cells recombine with the other pancreas cells into islets again.
The researchers transplanted three hundred islets into the leg muscles of each mouse with type 1 diabetes. They gave some mice human islets containing the genetically engineered beta cells and gave others human islets which they hadn’t changed. The scientists watched what happened to the beta cells over the next month.
The islets containing non-engineered beta cells were fully rejected and destroyed by the mice’s immune system over seven to 10 days. In these mice, the transplanted cells had no effect on the animals’ blood glucose levels, and the mice had no c-peptide (a measure of insulin) after one month.
Meanwhile, all the genetically engineered beta cells survived for the entire month without being attacked by the immune system. They also connected with their blood supply and stabilised the mice’s blood glucose levels after just two weeks.
Before any treatment can be tested on people in clinical trials, they must first be given to animals in tests called preclinical trials. This is to ensure we only test the safest and most effective therapies on humans to lower any potential risks. The mice the researchers used had type 1 diabetes and were ‘humanised’, meaning they had human immune cells instead of mouse immune cells. Also, the islets the researchers transplanted were from humans. Both these features make the study as relevant to people with type 1 as possible.
Currently, islet transplants containing functioning beta cells from pancreas donors only last around five years before the immune system attacks them again. For this reason, the recipient needs to take immunosuppressant drugs, which increase their risk of infection and cancer. Lots of these transplanted islets are immediately destroyed by the immune system because it detects that they are not the recipient’s own cells. Those that survive are gradually destroyed by the autoimmune attack which destroyed the person’s original beta cells. For islet transplants to be more successful, we need to stop the immune system destroying them. The researchers in this study have achieved this by genetically engineering beta cells so that the immune system can’t find them.
These genetically engineered beta cells from human pancreases were more effective than the beta cells which have, so far, been grown in a lab from stem cells. These beta cells released insulin in response to rising glucose levels more effectively than the beta cells that researchers can currently grow in the lab. Find out more about our research on lab-grown beta cells.
Another advantage is that the beta cells used in this study didn’t require immunosuppressant drugs. The lab-grown beta cells currently being tested in clinical trials do need the recipient to take immunosuppressant drugs, although researchers are working hard to genetically engineer lab-grown beta cells to avoid the immune system attack, in a similar way to those used in this study.
The exciting results from this research project demonstrate a potential cure for type 1 diabetes. The researchers are waiting for the results from another clinical trial where non-engineered donor islets are being transplanted into people’s arm muscles. If this proves successful, they will design a clinical trial to transplant their genetically engineered islets into the arm muscles of people with type 1.
Access the full research paper at the Science Translational Medicine website.
A study we helped conduct, which has just been published, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the United Kingdom and Ireland. This will help guide future research to focus on what matters most to people living with the condition.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
